Trial · NCT03922321
Results by group29
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 29
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Any Treatment-emergent Adverse Event (TEAE), Serious AE (SAE), Treatment-related Adverse Event (AE), and Death During the 6-week Treatment Period | RVT-1401 | TEAEs | 7 | Participants | |
| Number of Participants With Any Treatment-emergent Adverse Event (TEAE), Serious AE (SAE), Treatment-related Adverse Event (AE), and Death During the 6-week Treatment Period | RVT-1401 | SAEs | 0 | Participants | |
| Number of Participants With Any Treatment-emergent Adverse Event (TEAE), Serious AE (SAE), Treatment-related Adverse Event (AE), and Death During the 6-week Treatment Period | RVT-1401 | Treatment-related AEs | 6 | Participants | |
| Number of Participants With Any Treatment-emergent Adverse Event (TEAE), Serious AE (SAE), Treatment-related Adverse Event (AE), and Death During the 6-week Treatment Period | RVT-1401 | Deaths | 0 | Participants | |
| Number of Participants With Clinically Significant Findings Related to Vital Signs | RVT-1401 | 0 | Participants | ||
| Number of Participants With a Change From Normal Physical Examination Findings at Baseline to Abnormal Physical Examination Findings at the End of the Study | RVT-1401 | 0 | Participants | ||
| Number of Participants With Clinically Significant Findings Related to Electrocardiograms (ECGs) | RVT-1401 | 0 | Participants | ||
| Percent Change From Baseline in Total Immunoglobulin G (IgG), IgG1, IgG2, IgG3, and IgG4 Levels | RVT-1401 | Total IgG (Week 6 and 7 combined) | -65.00 | Standard Deviation 10.78 | Percent change |
| Percent Change From Baseline in Total Immunoglobulin G (IgG), IgG1, IgG2, IgG3, and IgG4 Levels | RVT-1401 | Total IgG (Week 7) | -64.83 | Standard Deviation 17.65 | Percent change |
| Percent Change From Baseline in Total Immunoglobulin G (IgG), IgG1, IgG2, IgG3, and IgG4 Levels | RVT-1401 | IgG1 (Week 7) | -67.16 | Standard Deviation 18.89 | Percent change |
| Percent Change From Baseline in Total Immunoglobulin G (IgG), IgG1, IgG2, IgG3, and IgG4 Levels | RVT-1401 | IgG2 (Week 7) | -56.91 | Standard Deviation 24.66 | Percent change |
| Percent Change From Baseline in Total Immunoglobulin G (IgG), IgG1, IgG2, IgG3, and IgG4 Levels | RVT-1401 | IgG3 (Week 7) | -70.05 | Standard Deviation 21.71 | Percent change |
| Percent Change From Baseline in Total Immunoglobulin G (IgG), IgG1, IgG2, IgG3, and IgG4 Levels | RVT-1401 | IgG4 (Week 7) | -61.28 | Standard Deviation 16.25 | Percent change |
| Mean Change From Baseline in Levels of Anti-thyroid-stimulating Hormone Receptor (Anti-TSHR) Antibodies at Week 7 | RVT-1401 | Baseline | 19.72 | Standard Deviation 15.073 | international units/milliliter (IU/mL) |
| Mean Change From Baseline in Levels of Anti-thyroid-stimulating Hormone Receptor (Anti-TSHR) Antibodies at Week 7 | RVT-1401 | Week 7 | -10.59 | Standard Deviation 9.827 | international units/milliliter (IU/mL) |
| Mean Change From Baseline in Proptosis in the Study Eye and Non-study Eye at Week 7 | RVT-1401 | Baseline, study eye | 23.1 | Standard Deviation 3.34 | millimeter (mm) |
| Mean Change From Baseline in Proptosis in the Study Eye and Non-study Eye at Week 7 | RVT-1401 | Change from Baseline to Week 7, study eye | -1.25 | Standard Deviation 1.50 | millimeter (mm) |
| Mean Change From Baseline in Proptosis in the Study Eye and Non-study Eye at Week 7 | RVT-1401 | Baseline, non-study eye | 21.9 | Standard Deviation 3.63 | millimeter (mm) |
| Mean Change From Baseline in Proptosis in the Study Eye and Non-study Eye at Week 7 | RVT-1401 | Change from Baseline to Week 7, non-study eye | -1.25 | Standard Deviation 0.96 | millimeter (mm) |
| Number of Participants With an Overall Proptosis Response | RVT-1401 | 3 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03922321/results